Vertex Pharmaceuticals to Advance VX-548 Pain Drug After Positive Phase 2 Studies
March 31 2022 - 9:00AM
Dow Jones News
By Colin Kellaher
Vertex Pharmaceuticals Inc. on Thursday said it plans to advance
VX-548 into pivotal development after the investigational pain drug
showed positive results in a pair of Phase 2 proof-of-concept
studies.
The Boston drug maker said VX-548 met the primary endpoint in
both studies of acute pain following abdominoplasty or bunionectomy
surgery.
Vertex said VX-548 was generally well tolerated, and it plans to
advance the drug into pivotal development in acute pain in the
second half of the year following discussions with regulators.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2022 08:45 ET (12:45 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024
